Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., is a biopharmaceutical company developing innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes.
COEPâs exclusive license deal with Deverra for DVX201, two products â54â & â16â provides access to Deverraâs no-HLA-matching platform asset.